This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Analysts upgraded SAFE, CNOB, LMT and more.
Stocks · News reference
Turn Therapeutics' GX-03 Named 'Developmental Immunology Solution of the Year'
Turn Therapeutics Inc. announced that its GX-03 therapy has been recognized as the 'Developmental Immunology Solution of the Year' in the 2026 BioTech Breakthrough Awards.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
BTIG to Host Virtual Fireside Chat with Turn Therapeutics
Turn Therapeutics Inc. is scheduled to participate in a virtual fireside chat hosted by BTIG to discuss the development program for its lead therapeutic candidate, GX-03.
8-K filing — Turn Therapeutics Inc. (TTRX)
Filed: 2026-10-07 AccNo: 0001213900-26-107329 Size: 23 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
This Ares Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: ARES Overweight, $150; MGEE Neutral, $76; TTRX Buy, $24; QNCX Buy, $70; EFSC Buy, $70.
LUCID CAPITAL MARKETS Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $24
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $24.
WBB Securities Downgrades Turn Therapeutics to Sell, Announces $10 Price Target
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sell and announces $10 price target.